The diagnostic value of RASSF1A promoter methylation in prostate cancer: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Su-Liang Li ◽  
Ye-Xing Li ◽  
Yun Ye ◽  
Xiao-Hua Yuan ◽  
Jian-Jun Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Promoter Methylation ◽  
Predictive Accuracy ◽  
Meta Analysis ◽  
Methylation Status ◽  
Diagnostic Value ◽  
Cochrane Library ◽  
Comprehensive Search ◽  
Larger Sample

AbstractBackgroundRASSF1A promoter methylation is consistent with clinicopathological data and has good accuracy in distinguishing tumors. However, the diagnostic parameters vary among previous studies. A systematic review was conducted to explore the diagnostic value of RASSF1A promoter methylation in prostate cancer.MethodsA comprehensive search of the literature in the PubMed, Medline, Cochrane Library, Embase and ISI Web of Science databases up to May 21, 2020 was performed. STATA software version 12.0 and Meta-disc version 1.4 were used to analyze the data.ResultsThe pooled sensitivity was 0.64 (95% CI 0.61–0.66), the pooled specificity was 0.80 (95% CI 0.77–0.83), the PLR was 3.82 (95% CI 1.96–7.44), and the NLR was 0.29 (95% CI 0.16–0.52). Furthermore, the pooled DOR of RASSF1A promoter methylation for prostate cancer was 13.08 (95% CI: 6.56–26.08). The area under the summary ROC curve was 0.87 (95% CI: 0.84–0.90). The results of the meta-regression suggested that heterogeneity was mainly derived from publication year. Fagan’s nomogram showed that the predictive accuracy was increased significantly by detecting RASSF1A promoter methylation for diagnosing prostate cancer.ConclusionThis meta-analysis suggests that detection of the RASSF1A promoter methylation status can be used for the diagnosis of PCa. In the future, further analyses and studies of larger sample sizes in large centers are needed to confirm our conclusion.

scholarly journals Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Jiale Sun ◽  
Yuxin Lin ◽  
Xuedong Wei ◽  
Jun Ouyang ◽  
Yuhua Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Early Detection ◽  
Publication Bias ◽  
Detection Rate ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Recurrent Prostate Cancer ◽  
Pet Ct ◽  
Statistical Heterogeneity

Background: Prostate-specific membrane antigen (PSMA)-targeted 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) positron emission tomography/computed tomography (PET/CT) has shown advantages in primary staging, restaging, and metastasis detection of prostate cancer (PCa). However, little is known about the role of 18F-DCFPyL PET/CT in biochemically recurrent prostate cancer (BRPCa). Hence, we performed a systematic review and meta-analysis to evaluate 18F-DCFPyL PET/CT as first-line imaging modality in early detection of BRPCa.Methods: A comprehensive literature search of PubMed, Web of Science, Embase, and Cochrane Library was conducted until December 2020. The pooled detection rate on a per-person basis and together with 95% confidence interval (CI) was calculated. Furthermore, a prostate-specific antigen (PSA)-stratified performance of detection positivity was obtained to assess the sensitivity of 18F-DCFPyL PET/CT in BRPCa with different PSA levels.Results: A total of nine eligible studies (844 patients) were included in this meta-analysis. The pooled detection rate (DR) of 18F-DCFPyL PET/CT in BRPCa was 81% (95% CI: 76.9–85.1%). The pooled DR was 88.8% for PSA ≥ 0.5 ng/ml (95% CI: 86.2–91.3%) and 47.2% for PSA < 0.5 ng/ml (95% CI: 32.6–61.8%). We also noticed that the regional lymph node was the most common site with local recurrence compared with other sites (45.8%, 95% CI: 42.1–49.6%). Statistical heterogeneity and publication bias were found.Conclusion: The results suggest that 18F-DCFPyL PET/CT has a relatively high detection rate in BRPCa. The results also indicate that imaging with 18F-DCFPyL may exhibit improved sensitivity in BRPCa with increased PSA levels. Considering the publication bias, further large-scale multicenter studies are warranted for validation.

scholarly journals The diagnostic value of miRNA-141 in prostate cancer: a systematic review and meta-analysis

2020 ◽  
Vol 4 (1) ◽  
pp. 53-59
Author(s):  
Yun Ye ◽  
◽  
Xiaohua Yuan ◽  
Jianjun Wang ◽  
Yuchen Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Diagnostic Value

scholarly journals Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis

Sarcoma ◽  
2020 ◽  
Vol 2020 ◽  
pp. 1-6 ◽  
Author(s):  
Marc El Beaino ◽  
Daniel C. Jupiter ◽  
Tarek Assi ◽  
Elie Rassy ◽  
Alexander J. Lazar ◽  
...  
Keyword(s):  
Systematic Review ◽  
Synovial Sarcoma ◽  
Predictive Value ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Cochrane Library ◽  
Specific Marker ◽  
Eligibility Criteria ◽  
Depth Analysis ◽  
The Mean

Background. Synovial sarcoma can present morphologically in multiple forms, including biphasic and monophasic subtypes. As a result, the histological diagnosis can sometimes be challenging. Transducin-Like Enhancer 1 (TLE1) is a transcriptional corepressor that normally is involved in embryogenesis and hematopoiesis but is also expressed in certain tumors. This systematic review examines the potential role of TLE1 as a diagnostic biomarker for the synovial sarcoma. Materials and Methods. A literature review and meta-analysis were conducted using the electronic databases Pubmed, the Cochrane Library, and Google Scholar. Thirteen studies met our eligibility criteria and were selected for in-depth analysis. Results. The mean sensitivity and specificity of TLE1 in detecting synovial sarcoma were 94% (95% CI 91%–97%) and 81% (95% CI 72%–91%), respectively, when all studies were aggregated together. The mean positive predictive value (PPV) of TLE1 was 75% (95% CI 62%–87%), whereas the negative predictive value (NPV) was 96% (95% CI 93%–98%). Conclusion. TLE1 is a sensitive and specific marker for synovial sarcoma that can aid in its diagnosis. Due to its involvement in several relevant signaling pathways, TLE1 might have direct relevance to the pathophysiology of the disease.

Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 150-150 ◽  
Author(s):  
Maxine Sun ◽  
Alexander Cole ◽  
Nawar Hanna ◽  
Adam S. Kibel ◽  
Toni K. Choueiri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cognitive Function ◽  
Cognitive Decline ◽  
English Language ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Cochrane Library ◽  
Significant Heterogeneity ◽  
The Impact

150 Background: Nearly 50% of men diagnosed with prostate cancer may receive treatment with some form of androgen deprivation therapy (ADT). While some side effects of ADT are well acknowledged, the specific impact of ADT on cognitive function is uncertain. Our objective was to perform a systematic review and meta-analysis assessing the impact of ADT on overall cognitive decline, and the risks of Alzheimers, Parkinson’s disease. Methods: Relevant studies were identified through search of English language articles indexed in PubMed Medline, PsycINFO, Cochrane Library and Web of Knowledge/Science. First, we assessed rates of cognitive decline in five cohorts from three studies. Second, we assessed rates of Alzheimer’s or Parkinson disease using three large retrospective studies. A pooled-analysis was conducted using a meta-analysis. Weighted averages were reported as odds ratios (OR) with 95% confidence intervals (CI) using RevMan and a DerSimonian and Laird random-effects model. The heterogeneity test was measured using the Q-Mantel-Haenszel ( P< 0.10 was considered of significant heterogeneity). Results: With respect to overall cognitive decline (defined as scoring 1.5 standard deviations [SD] in two or more objective cognitive tests), patients receiving ADT had higher odds of overall cognitive decline than patients with prostate cancer not treated with ADT or health controls (OR: 2.03, 95% CI: 1.42–2.90). Furthermore, men with a history of ADT for prostate cancer had higher odds of developing Alzheimer’s and Parkinson dementia compared to men with prostate cancer not treated with ADT (OR: 1.32, 95% CI: 1.27–1.37). Conclusions: Men receiving ADT for prostate cancer performed significantly worse on measures of overall cognitive function. Additionally, results from the three large observational trials included suggest men exposed to ADT for prostate cancer have higher rates of Parkinson/Alzheimer’s compared to men without ADT.

Regorafenib-associated adverse event management in colorectal and gastrointestinal stromal cancer patients: A systematic review and meta-analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15181-e15181
Author(s):  
Ganfeng Xie ◽  
Yuzhu Gong ◽  
Shuang Wu ◽  
Chong Li ◽  
Songtao Yu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Initial Dose ◽  
Preventive Measures ◽  
Meta Analysis ◽  
Pearson Correlation ◽  
Management Strategies ◽  
Cochrane Library ◽  
Delayed Treatment ◽  
Comprehensive Search

e15181 Background: Adverse events (AEs) observed in regorafenib treated metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors (GIST) often require treatment modification. However, due to dearth of literature reporting AE management, we performed a systematic review and meta-analysis to assess the success of different methods of managing regorafenib-associated AEs and also determined risk factors of the AEs. Methods: A comprehensive search was conducted in PubMed, Embase and Cochrane Library, to retrieve RCTs and observational studies published from inception to May 2018, discussing the management methods of AEs with rate of improvement and risk factors of the AEs. The success rate for each method was evaluated as percentage and compared using chi2-test. Risk factors were presented using Pearson correlation. Results: We identified 28 studies for this analysis (N = 3120 patients; 305 GIST and 2,815 mCRC). Methods used for management included intermittent dose withdrawal (66.7%), delayed treatment schedules (54%), dose reductions (41%), complete drug withdrawal (19%) and preventive measures like dexamethasone and lactose administration or surgery (63.7%). Reduction or improvement in AEs was observed in 57%, 17% and 100% patients after lowering the initial dose, intermittent withdrawal of regorafenib and using other preventive measures, respectively. Patients aged < 65 years had significantly higher occurrence of AEs compared with patients aged ≥65 years (27.6% vs. 71.3%, p = 0.001). A significant positive correlation was observed between the occurrence of all and grade 3AEs with 160mg dose (r = 0.967 and 0.746 respectively; p = 0.001 for both) with no significant correlation observed for 120-mg and 80-mg doses and any gender. Conclusions: Initiating dose of 160mg is a major risk factor for regorafenib associated AEs in mCRC and GIST patients; with intermittent dose reduction, withdrawal, and delayed treatment being the commonly used management strategies. To allay the risk of AEs and maintain the efficacy, 120mg initial dose is recommended for mCRC and GIST patients. However, further studies are required to confirm the results.

scholarly journals Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis

2021 ◽  
Author(s):  
MY Cynthia Stafford ◽  
Colin E Willoughby ◽  
Colum P Walsh ◽  
Declan J McKenna
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Disease Progression ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Risk Groups ◽  
Cochrane Library ◽  
Clinical Biomarker ◽  
Meta Analyses ◽  
The Relationship

Elevated levels of miR-21 expression are associated with many cancers, suggesting it may be a promising clinical biomarker. In prostate cancer (PCa), however, there is still no consensus about the usefulness of miR-21 as an indicator of disease progression. This systematic review and meta-analysis was conducted to investigate the value of miR-21 expression as a prognostic measurement in PCa patients. Medline (Ovid), EMBASE, Web of Science, Scopus and Cochrane Library databases were systematically searched for relevant publications between 2010 to 2021. Studies exploring the relationship between miR-21 expression, PCa prognosis and clinicopathological factors were selected for review. Those reporting hazard ratio (HR) and 95% confidence intervals (CIs) were subject to meta-analyses. Fixed-effect models were employed to calculated pooled HRs and 95% CIs. Risk of bias in each study was assessed using QUIPS tool. Certainty of evidence in each meta-analysis was assessed using GRADE guidelines. A total of 64 studies were included in the systematic review. Of these, 11 were eligible for inclusion in meta-analysis. Meta-analyses revealed that high miR-21 expression was associated with poor prognosis: HR=1.58 (95% CI=1.19-2.09) for biochemical recurrence, MODERATE certainty; HR=1.46 (95% CI=1.06-2.01) for death, VERY LOW certainty; and HR=1.26 (95% CI=0.70-2.27) for disease progression, VERY LOW certainty. Qualitative summary revealed elevated miR-21 expression was significantly positively associated with PCa stage, Gleason score and risk groups. This systematic review and meta-analysis suggests that elevated levels of miR-21 are associated with poor prognosis in PCa patients. miR-21 expression may therefore be a useful prognostic biomarker in this disease.

Correlation between PSA kinetics and detection rate of PSMA-PET in the setting of biochemical recurrent prostate cancer: A systematic review and meta-analysis.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 71-71
Author(s):  
Ricardo Pereira Mestre ◽  
Giorgio Treglia ◽  
Matteo Ferrari ◽  
Mariarosa Pascale ◽  
Calogero Mazzara ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Detection Rate ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Cochrane Library ◽  
Recurrent Prostate Cancer ◽  
Psa Kinetics ◽  
Psma Pet ◽  
Statistical Heterogeneity

71 Background: Serum prostate-specific antigen (PSA) may predict the risk of positive positron emission tomography/computed tomography with radiolabeled prostate-specific membrane antigen (PSMA-PET/CT) in patients with biochemical recurrent prostate cancer (BRPCa). However, to date, there are no clear data regarding the correlation between PSA kinetics and PSMA-PET findings. We performed a systematic review and meta-analysis to provide evidence-based data in this setting. Methods: A comprehensive literature search of studies published through October 2018 in PubMed/MEDLINE, EMBASE and Cochrane library databases was performed. A meta-analysis to establish the detection rate (DR) of PSMA-PET using different cut-off values of PSA doubling time (PSAdt) and a pooled analysis to establish whether shorter PSAdt may predict positive PSMA-PET results was performed in patients with BRPCa. Results: Twelve articles were included in the systematic review and eight articles (including 1398 patients) were selected for the meta-analysis. The pooled DR including 95% confidence intervals (95% CI) of PSMA-PET in restaging prostate cancer (PCa) patients was 72% (95% CI: 60-82%), increasing to 83% (95% CI: 75-90%) when PSAdt was ≤ 6 months and decreasing to 60% (95% CI: 37-80%) when PSAdt was > 6 months. PSAdt ≤ 6 months may predict the positive result of PSMA-PET (pooled odds ratio: 3.22; 95% CI: 1.17-8.88). Statistical heterogeneity among the included studies was found. Conclusions: PSA kinetics, and in particular shorter PSAdt, may be predictor of PSMA-PET positivity in patients with BRPCa. Further larger studies in this setting are warranted.

scholarly journals Urinary EN-2 to predict prostate cancer: Systematic review and meta-analysis

2017 ◽  
Vol 63 (7) ◽  
pp. 656-661 ◽  
Author(s):  
Maria Inês da Rosa ◽  
Eduardo Ronconi Dondossola ◽  
Maria Cecilia Manenti Alexandre ◽  
Kristian Madeira ◽  
Florentino de Araújo Cardoso ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Meta Analysis ◽  
Specific Antigen ◽  
High Specificity ◽  
Cochrane Library ◽  
Language Restriction ◽  
Comprehensive Search ◽  
Control Disease ◽  
Low Sensitivity ◽  
Abstract Screening

Summary Introduction: Prostate cancer is the second type of cancer diagnosed and the fifth cause of death in men worldwide. Early diagnosis helps to control disease progression. Currently, prostate specific antigen is the standard biomarker, as it has a broad scope of identification and, thus, new and more specific biomarkers must be studied. Objective: To evaluate the accuracy of engrailed-2 protein (EN2) in urine as a prostate cancer biomarker. Method: A comprehensive search was conducted in the period from January 2005 to July 2016 using the following electronic databases: Medline (PubMed), Embase, Cochrane Library and Lilacs. The keywords used in the databases were: "engrailed-2," "EN2," "prostatic neoplasms." The search was limited to humans and there was no language restriction. Critical appraisal of the included studies was performed according to Quadas-2. Statistical analysis was performed using Meta-DiSc® and RevMan 5.3 softwares. Results: A total of 248 studies were identified. After title and abstract screening, 231 studies were removed. A total of 17 studies were read in full and two studies were included in the meta-analysis. The pooled sensitivity was 66% (95CI 0.56-0.75) and specificity was 89% (95CI 0.86-0.92). The DOR was 15.08 (95CI 8.43-26.97). Conclusion: The EN2 test showed high specificity (89%) and low sensitivity (66%).

Marginal Accuracy of Milled Versus Cast Cobalt Chromium Alloys in Long Span Implant-Supported Frameworks: A Systematic Review and Meta-analysis

2020 ◽  
Vol 11 (2) ◽  
pp. 120-127
Author(s):  
Simone Shah ◽  
Deepak Nallaswamy ◽  
Dhanraj Ganapathy
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Cobalt Chromium ◽  
Exclusion Criteria ◽  
Long Span ◽  
Electronic Search ◽  
Chromium Alloys ◽  
Randomised Control Trials ◽  
Larger Sample

Aim: To assess if milled cobalt chromium (Co-Cr) alloy offers significantly better marginal accuracy than cast Co-Cr alloy for screw-retained long-span dental implant framework. Materials and Methods: A search PICO was formulated using suitable keywords and an electronic search was initiated. The databases of PubMed, Cochrane Library, Google Scholar and Embase were searched for related articles. Bibliographies of randomised control trials and reviews, identified in the electronic search, were analysed for studies published outside the electronically searched journals. Electronic search identified 26 studies. A total of 16 studies were eliminated after reading the abstracts. Out of the remaining 10 studies, 3 were eliminated based on the inclusion and exclusion criteria, and finally 7 studies were finalised for systematic review. Results Data were extracted from the included studies and analysed. The obtained data were suitable for meta-analysis, which showed an overall effect size z = 4.97 ( P < .001) at 95% CI showing a significant statistical difference between milled and cast Co-Cr frameworks. Conclusion: Milled cobalt chromium frameworks are significantly more accurate than cast frameworks for long-span implant-supported frameworks used in dental prosthetic rehabilitation. More randomized controlled trials need to be conducted with a larger sample size to get a more authentic conclusion in a clinical scenario.

scholarly journals Association between RASSF1A Promoter Methylation and Prostate Cancer: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e75283 ◽  
Author(s):  
Jincheng Pan ◽  
Junxing Chen ◽  
Bo Zhang ◽  
Xu Chen ◽  
Bin Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Promoter Methylation ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document